Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Shanghai's Zenas Acquires CD19 Antibody from Xenco in $480 Million Deal

Week in Review: BeiGene Cleared to Stage $3 Billion IPO on Shanghai STAR Exchange

Week in Review: Zai Lab Announces Two In-Licensings with Total Value of $800 Million

Week in Review: Two China Affiliated Biopharmas Raise $585 Million in IPOs

Week in Review: Fosun Pharma Acquires Majority Stake in China Vaccine Company for $682 Million

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China